Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

British Journal of Haematology

Volumn 148, Issue 3, 2010, Pages 466-475

  Farmaki, Kallistheni ^a   Tzoumari, Ioanna ^a   Pappa, Christina ^a   Chouliaras, Giorgos ^b   Berdoukas, Vasilios ^b  

^a General Hospital of Corinth   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cardiomyopathy; Combined chelation; Endocrinopathy; Iron overload; Thalassaemia

Indexed keywords

ANTIBIOTIC AGENT; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; TESTOSTERONE; THYROXINE;

ADULT; ANDROGEN THERAPY; ARTHROPATHY; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; EYE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART DISEASE; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MALE; MONOTHERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; SUPPLEMENTATION; THALASSEMIA MAJOR; TINNITUS; TONSILLITIS;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD GLUCOSE; BLOOD TRANSFUSION; CARDIOMYOPATHIES; CHILD; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOCRINE SYSTEM DISEASES; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; PYRIDONES; THYROXINE; YOUNG ADULT;

EID: 74049116227     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07970.x     Document Type: Article

References (50)

1. Aessopos, A., Fragodimitri, C., Karabatsos, F., Hatziliami, A., Yousef, J., Giakoumis, A., Dokou, A., Gotsis, E.D., Berdoukas, V. Karagiorga, M. (2007) Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica, 92, 131 132. (Pubitemid 46232670)
2. Aessopos, A., Berdoukas, V. Tsironi, M. (2008) The heart in transfusion dependent homozygous thalassaemia today - prediction, prevention and management. European Journal of Haematology, 80, 93 106.
3. Anderson, L.J., Westwood, M.A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J.B., Walker, J.M. Pennell, D.J. (2004) Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 127, 348 355.
4. Angelopoulos, N.G., Zervas, A., Livadas, S., Adamopoulos, I., Giannopoulos, D., Goula, A. Tolis, G. (2006) Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabetic Medicine, 23, 1327 1331.
5. Au, W.Y., Lam, W.W., Chu, W., Tam, S., Wong, W.K., Liang, R. Ha, S.Y. (2008) A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica, 93, 116 119.
6. Biondi, B. Cooper, D.S. (2008) The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29, 76 131.
7. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. Cnaan, A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89, 1187 1193.
8. Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., Ghilardi, R., Origa, R., Piga, A., Romeo, M.A., Zhao, H. Cnaan, A. (2005) Survival and complications in thalassemia. Annals of the New York Academy of Sciences, 1054, 40 47.
9. Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A., Romeo, M.A., Zhao, H. Cnaan, A. (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107, 3733 3737.
10. Cario, H., Holl, R.W., Debatin, K.M. Kohne, E. (2003a) Disproportionately elevated fasting proinsulin levels in normoglycemic patients with thalassemia major are correlated to the degree of iron overload. Hormone Research, 59, 73 78.
11. Cario, H., Holl, R.W., Debatin, K.M. Kohne, E. (2003b) Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. European Journal of Pediatrics, 162, 139 146.
12. Caro, J.J., Ward, A., Green, T.C., Huybrechts, K., Arana, A., Wait, S. Eleftheriou, A. (2002) Impact of thalassemia major on patients and their families. Acta Haematologica, 107, 150 157.
13. Christoforidis, A., Perifanis, V. Athanassiou-Metaxa, M. (2006) Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. British Journal of Haematology, 135, 271 272.
14. Cooper, D.S. (2001) Clinical practice. Subclinical hypothyroidism. New England Journal of Medicine, 345, 260 265.
15. Cunningham, M.J., Macklin, E.A., Neufeld, E.J. Cohen, A.R. (2004) Complications of beta-thalassemia major in North America. Blood, 104, 34 39.
16. De Sanctis, V., Eleftheriou, A. Malaventura, C. (2004) Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatric Endocrinology Reviews, 2 (Suppl. 2 249 255.
17. De Sanctis, V., De Sanctis, E., Ricchieri, P., Gubellini, E., Gilli, G. Gamberini, M.R. (2008) Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. Pediatric Endocrinology Reviews, 6 (Suppl. 1 174 180.
18. Dolgin, M. (1994) Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Little Brown and Company, New York.
19. Engle, M.A., Erlandson, M. Smith, C.H. (1964) Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation, 30, 698 705.
20. Farmaki, K., Angelopoulos, N., Anagnostopoulos, G., Gotsis, E., Rombopoulos, G. Tolis, G. (2006) Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. British Journal of Haematology, 134, 438 444.
21. Fink, H. (1964) Transfusion hemochromatosis in Cooley's anemia. Annals of the New York Academy of Sciences, 119, 680 685.
22. Gabutti, V. Piga, A. (1996) Results of long-term iron-chelating therapy. Acta Haematologica, 95, 26 36.
23. Gamberini, M.R., Fortini, M., De Sanctis, V., Gilli, G. Testa, M.R. (2004) Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatric Endocrinology Reviews, 2 (Suppl. 2 285 291.
24. Gharib, H., Tuttle, R.M., Baskin, H.J., Fish, L.H., Singer, P.A. McDermott, M.T. (2005) Consensus statement #1: subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. Thyroid, 15, 24 28. (Pubitemid 40223495)
25. Giardina, P.J. Grady, R.W. (2001) Chelation therapy in beta-thalassemia: an optimistic update. Seminars in Hematology, 38, 360 366.
26. Hoffbrand, A.V. (2005) Deferiprone therapy for transfusional iron overload. Best Practice & Research. Clinical Haematology, 18, 299 317.
27. Hoffbrand, A.V., Cohen, A. Hershko, C. (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 102, 17 24.
28. Kattamis, C., Ladis, V., Tsoussis, D., Kaloumenou, I. Theodoridis, C. (2004) Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatric Endocrinology Reviews, 2 (Suppl. 2 267 271.
29. Link, G., Konijn, A.M., Breuer, W., Cabantchik, Z.I. Hershko, C. (2001) Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. Journal of Laboratory and Clinical Medicine, 138, 130 138.
30. Maggio, A., Vitrano, A., Capra, M., Cuccia, L., Gagliardotto, F., Filosa, A., Magnano, C., Rizzo, M., Caruso, V., Gerardi, C., Argento, C., Campisi, S., Cantella, F., Commendatore, F., D'Ascola, D.G., Fidone, C., Ciancio, A., Galati, M.C., Giuffrida, G., Cingari, R., Giugno, G., Lombardo, T., Prossomariti, L., Malizia, R., Meo, A., Roccamo, G., Romeo, M.A., Violi, P., Cianciulli, P. Rigano, P. (2009) Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells, Molecules, and Diseases, 42, 247 251.
31. Melchionda, N., Forlani, G., Marchesini, G., Baraldi, L. Natale, S. (2002) WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance. International Journal of Obesity and Related Metabolic Disorders, 26, 90 96.
32. Merkel, P.A., Simonson, D.C., Amiel, S.A., Plewe, G., Sherwin, R.S., Pearson, H.A. Tamborlane, W.V. (1988) Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. New England Journal of Medicine, 318, 809 814.
33. Miskin, H., Yaniv, I., Berant, M., Hershko, C. Tamary, H. (2003) Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. European Journal of Haematology, 70, 398 403.
34. Modell, B., Khan, M. Darlison, M. (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet, 355, 2051 2052.
35. Modell, B., Khan, M., Darlison, M., Westwood, M.A., Ingram, D. Pennell, D.J. (2008) Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 10, 42.
36. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B. Galanello, R. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107, 3738 3744.
37. Piga, A., Gaglioti, C., Fogliacco, E. Tricta, F. (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica, 88, 489 496.
38. Sohn, Y.S., Breuer, W., Munnich, A. Cabantchik, Z.I. (2008) Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood, 111, 1690 1699.
39. St Pierre, T.G., Clark, P.R., Chua-anusorn, W., Fleming, A.J., Jeffrey, G.P., Olynyk, J.K., Pootrakul, P., Robins, E. Lindeman, R. (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 105, 855 861. (Pubitemid 40070775)
40. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. Pennell, D.J. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876 1884.
41. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Pibiri, M., Nair, S.V., Walker, J.M. Pennell, D.J. (2008) Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance, 10, 12.
42. Tavecchia, L., Masera, N., Russo, P., Ciro, A., Vincenzi, A., Vimercati, C. Masera, G. (2006) Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica, 91, ECR19.
43. Telfer, P., Coen, P.G., Christou, S., Hadjigavriel, M., Kolnakou, A., Pangalou, E., Pavlides, N., Psiloines, M., Simamonian, K., Skordos, G., Sitarou, M. Angastiniotis, M. (2006) Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica, 91, 1187 1192.
44. Thomas, R.M. Skalicka, A.E. (1980) Successful pregnancy in transfusion-dependent thalassaemia. Archives of Disease in Childhood, 55, 572 574.
45. Tsironi, M., Deftereos, S., Andriopoulos, P., Farmakis, D., Meletis, J. Aessopos, A. (2005) Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. European Journal of Haematology, 74, 84 85.
46. Tuck, S.M., Jensen, C.E., Wonke, B. Yardumian, A. (1998) Pregnancy management and outcomes in women with thalassaemia major. Journal of Pediatric Endocrinology and Metabolism, 11 (Suppl. 3 923 928.
47. Wonke, B., Wright, C. Hoffbrand, A.V. (1998) Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology, 103, 361 364.
48. Wood, J.C., Enriquez, C., Ghugre, N., Tyzka, J.M., Carson, S., Nelson, M.D. Coates, T.D. (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 106, 1460 1465.
49. Wu, K.H., Chang, J.S., Tsai, C.H. Peng, C.T. (2004) Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Annals of Hematology, 83, 471 473.
50. Zanninelli, G., Glickstein, H., Breuer, W., Milgram, P., Brissot, P., Hider, R.C., Konijn, A.M., Libman, J., Shanzer, A. Cabantchik, Z.I. (1997) Chelation and mobilization of cellular iron by different classes of chelators. Molecular Pharmacology, 51, 842 852.